TEVA - Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.